



## **TLC to Present at HC Wainwright & Co. 22<sup>nd</sup> Annual Global Investment Conference**

**SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – September 9, 2020 – [TLC](#)** (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company's President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co's 22<sup>nd</sup> Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET.

The 20-minute live presentation will include a company overview and update by Mr. Yeh, with analyses of data on TLC's pain programs – [TLC599](#) and [TLC590](#) – by Dr. Spencer-Green. During the virtual conference, which will take place September 14-16, 2020, TLC will also be participating in one-on-one sessions.

The corporate slide deck used during the live presentation will be available on the company's website at [www.tlcbio.com](http://www.tlcbio.com) in the Investors section, under News & Events.

### **About TLC**

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.

### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLC's annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC's expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

### **Contact**

Dawn Chi / Corporate Communications / [dawn@tlcbio.com](mailto:dawn@tlcbio.com)